Clinical Trials Browser

Enrolling by invitation × INDUSTRY × Other hematologic neoplasm × Clear all

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT05332054 2026-03-12

LTFS

Enrolling by invitation

150 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT05041309 2026-02-25

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Enrolling by invitation

1,000 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Phase 2 Enrolling by invitation

332 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06788509 2025-10-10

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Phase 1 Enrolling by invitation

80 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT06208878 2025-08-14

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Enrolling by invitation

70 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT06925685 2025-04-13

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Enrolling by invitation

50 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT05509855 2024-11-20

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Enrolling by invitation

44 enrolled

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

PERSIST

LTFS

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007